Other · developed by ModeX Therapeutics, An OPKO Health Company
MDX2003 is an agent given by intravenous infusion. It is studied in B-cell lymphomas, including diffuse large B-cell lymphoma, follicular lymphoma and Waldenström macroglobulinemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07249905 | Phase 1/2 | Lymphoma | Recruiting | OPK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
DLBCL - Diffuse Large B Cell LymphomaFL LymphomaFollicular Lymphoma (FL)HGBCLLymphomaLymphoplasmacytic LymphomaPMBCLWaldenström Macroglobulinemia (WM)
Updated Oct 25, 2026. Something wrong or missing? Report it on the OPK page.
See OPK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OPK catalysts and pipeline →